IPO - BIOVIE INC.

Form Type: S-1

Filing Date: 2025-07-03

Corporate Action: Ipo

Type: New

Accession Number: 000152013825000198

Filing Summary: On July 3, 2025, BioVie Inc. filed its registration statement on Form S-1 with the SEC. The company is offering 1,456,310 units in a firm commitment underwritten offering, each consisting of one share of Class A Common Stock and one warrant to purchase one share of Class A Common Stock at an assumed public offering price of $10.30 per Unit. In addition, BioVie is offering 1,456,310 pre-funded units, each comprising one pre-funded warrant to purchase one share of Class A Common Stock and one warrant to purchase one share of Class A Common Stock. Each warrant will have an exercise price of $12.875 and will expire five years from the date of issuance. The special meeting of stockholders on June 23, 2025, approved a reverse stock split of the outstanding shares of Common Stock at a ratio of 1-for-10, effective July 7, 2025. The anticipated use of proceeds and details of underwriting discounts and commissions were also discussed. The company is positioned as a clinical-stage entity focused on developing therapies for neurodegenerative diseases and requires funding for its drug candidates, including bezisterim for Alzheimer’s and Parkinson’s diseases and BIV201 for advanced liver cirrhosis. The document also emphasizes the high risk involved in investing in BioVie’s Common Stock, aligning with emerging growth company status, and sets forth the company’s strategic plan moving forward.

Form Type: DRS

Filing Date: 2025-05-15

Corporate Action: Ipo

Type: New

Accession Number: 000152013825000149

Filing Summary: BioVie Inc. filed a DRS registration statement as part of its initial public offering (IPO) process, aiming to offer units consisting of Class A common stock and warrants. The company is engaging in a firm commitment underwritten offering, which includes both standard units and pre-funded units for specific investors. They clarified the condition for investors whose holdings may exceed ownership limits. The prospectus highlights that this is a clinical-stage company focused on drug therapies for neurodegenerative diseases and advanced liver diseases, with emerging drug candidates like bezisterim showing promise in treating conditions such as Alzheimer's disease, Parkinson's disease, and long COVID. The document references an extensive catalogue of past studies, promising initiatives, and future development plans, particularly focusing on the company's recent clinical trials, risk factors, and the economic impact the company aims to address through its therapies. The underwriters have a 45-day overallotment option to purchase additional shares, indicating significant interest and planned outreach for public engagement in the offering. Additionally, they outlined the risk statements about investments in their stock, emphasizing the associated degrees of risk in the clinical trial phases. The offering's pricing structure indicated potential underwriting discounts, and the document includes investor-specific details on the use of proceeds and stock features, as well as legal considerations pertinent to the offering.